Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Journal of Bioethical Inquiry|July 20, 2005
Out of the armchair: a bioethics student's search for practical knowledge in KenyaNicole Li
Journal of Biopharmaceutical Statistics|January 22, 2024
A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trialsPingye Zhang, Xiaoyun Nicole Li
Journal of Biopharmaceutical Statistics|February 19, 2026
A simulation study comparing backfill and randomized expansion in oncology dose optimizationHuan Cheng, Xiaoyun Nicole Li
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|August 15, 2020
Female Authorship in Radiology: Trends in the Past Decade in CARJNicole Li, Mostafa Alabousi, Michael N Patlas
ANZ Journal of Surgery|October 3, 2022
Socioeconomic disadvantage and its impact on colorectal cancer in Australia: a scoping reviewNicole Li Tham, Anita Skandarajah, Ian Paul Hayes
Current Drug Metabolism|April 6, 2012
Effects of culture duration on gene expression of P450 isoforms, uptake and efflux transporters in primary hepatocytes cultured in the absence and presence of interleukin-6: implications for experimental design for the evaluation of downregulatory effects of biotherapeuticsQian Yang, Utkarsh Doshi, Nicole Li, et al.
Contemporary Clinical Trials|September 29, 2022
A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Contemporary Clinical Trials|July 9, 2018
Adaptive expansion of biomarker populations in phase 3 clinical trialsCong Chen, Xiaoyun Nicole Li, Wen Li, et al.
The Journal of Emergency Medicine|October 2, 2020
Acute Angle-Closure Glaucoma Secondary to Vitreous Hemorrhage Diagnosed with the Aid of Point-of-Care UltrasoundAndrew Jersey, Leland Perice, Nicole Li, et al.
Contemporary Clinical Trials|February 21, 2023
A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Pageof 8